Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine
| dc.contributor.author | Johnstone, Jennie | |
| dc.contributor.author | Tyrrell, Gregory J. | |
| dc.contributor.author | Marrie, Thomas J. | |
| dc.contributor.author | Garg, Sipi | |
| dc.contributor.author | Kellner, James D. | |
| dc.contributor.author | the Streptococcus pneumoniae Alberta Team (SPAT) group, | |
| dc.date.accessioned | 2018-09-27T11:58:01Z | |
| dc.date.available | 2018-09-27T11:58:01Z | |
| dc.date.issued | 2011-01-01 | |
| dc.date.updated | 2018-09-27T11:58:01Z | |
| dc.description.abstract | The objective of this study was to describe the epidemiology, clinical characteristics, microbiology and outcomes of patients of all ages with Streptococcus pneumoniae meningitis between 2000 and 2004; two years pre- and postintroduction of an S pneumoniae 7-valent conjugate vaccine program in Alberta in children younger than two years of age. The high mortality rate associated with S pneumoniae meningitis, despite appropriate therapy, suggests that prevention of S pneumoniae meningitis is critical. Despite implementation of a PCV-7 program in Alberta, rates of S pneumoniae meningitis in children younger than two years of age is still high. Thus, continued research into safe and efficacious vaccines covering a broader range of S pneumoniae serotypes is necessary.OBJECTIVE: To describe the epidemiology, clinical characteristics, microbiology and outcomes of patients of all ages with Streptococcus pneumoniae meningitis two years pre- and postintroduction of a S pneumoniae 7-valent conjugate vaccine program in Alberta in children ud_less_than2 years of age.METHODS: Between 2000 and 2004, all cases of invasive pneumococcal disease in Alberta were identified. From this cohort, patients with S pneumoniae meningitis were identified by chart review. Clinical data, laboratory data and in-hospital outcomes were collected.RESULTS: Of the 1768 cases of invasive pneumococcal disease identified between 2000 and 2004, 110 (6.2%) had S pneumoniae meningitis. The overall incidence was 0.7 per 100,000 persons and remained unchanged over the study period. The rate in children ud_less_than2 years of age appeared to fall over time, from 10.5 per 100,000 persons in 2000 to five per 100,000 persons in 2004, although there was insufficient evidence of a statistically significant time trend within any age group. Overall, the mean age was 30 years and 47% were male. In-hospital mortality was 20%, ranging from 6% in those ≤2 years of age to 31% for those ≥18 years of age, despite appropriate antimicrobial therapy.CONCLUSION: The high mortality rate associated with S pneumoniae meningitis suggests that prevention by vaccination is critical. In children ud_less_than2 years of age, there was a downward trend in the rate of S pneumoniae meningitis after implementation of the S pneumoniae 7-valent conjugate vaccine program, but rates were still high. | |
| dc.description.version | Peer Reviewed | |
| dc.identifier.citation | Jennie Johnstone, Gregory J. Tyrrell, Thomas J. Marrie, Sipi Garg, James D. Kellner, and the Streptococcus pneumoniae Alberta Team (SPAT) group, “Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 22, no. 4, pp. 137-141, 2011. doi:10.1155/2011/179170 | |
| dc.identifier.doi | https://doi.org/10.1155/2011/179170 | |
| dc.identifier.uri | http://hdl.handle.net/1880/108410 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/45582 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | Copyright © 2011 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
| dc.title | Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine | |
| dc.type | Journal Article |